(viability,3)
(toxic,1)
(DNA,14)
(﻿Cancer,1)
(Twist,2)
(bacterial,2)
(segmenting,1)
(neoadjuvant,4)
(previous,6)
(µT,1)
(discussed,4)
(analyses.In,1)
(ER + breast,3)
(advancements,1)
(evidence,7)
(end,3)
(levonorgestrel,1)
(PGF,1)
(oncogenes,1)
(Intervention,1)
(Pdii/Ptii,1)
(caused,3)
(histograms,1)
(1062,1)
(exchange,1)
(explore,2)
(Toxicity,1)
(conducted,11)
(purine,1)
(part,1)
(alone,5)
(adipose,2)
(process,9)
([OR],1)
(most,26)
(easily,1)
(EXTL,1)
(detectability,1)
(be,59)
(eight,1)
(inhibiting,1)
(chromatin,1)
(patient-based,1)
(axilla,1)
(32.1%,1)
(Americans,2)
(junctions,1)
(combination,14)
(supplying,1)
(16.4,1)
(p.Gln498Thrfs,1)
(cyst,2)
(larger,1)
(EVIDENCE,1)
(PIK3CA,2)
(scrutiny,1)
(ml,2)
(MSOT,6)
(levels,15)
(environment,1)
(cervical,1)
(0.02;,1)
(validating,1)
(Up,1)
(dramatically,1)
(rs2229571,1)
(interdependent,1)
(NMR,1)
(mitochondrial,2)
(multicatheter,1)
(small,9)
(UPR,1)
(necessary,4)
(36,1)
(AKT1,3)
(units,1)
(O,2)
(MEK,1)
(necessitating,1)
(pooled,2)
(at,31)
(heterogenic,1)
(∼20%,1)
(development,20)
(diffusion-weighted,1)
(Y1234/1235,1)
(epigastric,1)
(T/B,1)
(S,1)
(discussions,1)
(divided,1)
(3-dimensional,1)
(ex,1)
(accelerated,2)
(realised,1)
(maintenance,1)
(drains,1)
(10,1)
(8.56,1)
(encompasses,1)
(probably,1)
(Follow-up,1)
(0.001,3)
(understood,2)
(unable,1)
(0.12,1)
(transfer,2)
(1000,3)
(0.049,1)
(G2,1)
(co-occur,1)
(green,1)
(effective,7)
(broth,1)
(propensity,3)
(wound,2)
(diagnostic,8)
(months,5)
(management,8)
(desquamation,1)
(investigate,8)
(Library,2)
(fragments,2)
(importantly,1)
(approval,1)
(variation,5)
(undertaken,3)
(promotes,1)
(Forty-three,1)
(studies,26)
(population-based,2)
(existing,4)
(conclude,1)
(researchers,1)
(MAGN,1)
(71%,1)
(People,1)
(makers,1)
(Compared,1)
(annual,1)
(P<0.0001,2)
(E75,1)
(Efforts,1)
(BCL2A1,1)
(suggests,3)
(constructing,1)
(cancer-specific,7)
(characterization,1)
(36.5%,1)
(narrowing,1)
(regional,1)
(condition,2)
(frequently,6)
(BDH1,1)
(absorption,3)
(P=0.2,1)
(third,1)
(detecting,1)
(estradiol,2)
(present,19)
(regulate,2)
(glycosylation,3)
(adjusting,1)
(LoF,1)
(non-steroidal,1)
(passive,1)
(nAB,6)
(diabetes,1)
(lines,25)
(proanthocyanidins,1)
(do,1)
(proteasome,1)
(Higher,1)
(GSPs,6)
(anthracycline-based,1)
(SRB,1)
(entity,1)
(predictive,4)
(microcarcinoma,1)
(indicator,1)
(72,1)
(UTR,3)
(structure,3)
(1.06,1)
(Karachi,1)
(signals,1)
(ESI,1)
(ERα36,2)
(presence,6)
(early,12)
(confirmed,11)
(risk,45)
(pregnancies,1)
(eventually,2)
(13%,1)
(related,5)
(increment,1)
(non-metastatic,1)
(mixed,2)
(46.6%,1)
(PubMed,2)
(20-60 μg/ml,1)
(higher,21)
(protein,14)
(might,7)
(in vitro,2)
(backbone,1)
(offers,2)
(5-diphenyltetrazolium,1)
(3,7)
(anti-neoplastic,1)
(Kunitz,1)
(identified,18)
(coat,1)
(filters,1)
(comes,1)
(aspects,2)
(cocoon,1)
(pRESs,2)
(maximal,1)
(creation,1)
(stratified,1)
(managed,1)
(sericin,1)
(involved,14)
(clonogenic,3)
(carriers,2)
(trainees,1)
(Ongoing,1)
(25.6,1)
(expenses,1)
(45 years,1)
(Cooperative,1)
(differential,1)
(broader,1)
(future,4)
(9.7%,1)
(finally,1)
(mistaking,1)
(applicable,1)
(Database,2)
(age,11)
(respectively,7)
(motif,1)
(Collectively,1)
(ultrasound,4)
(immortalized,1)
(noncoding,4)
(changes,10)
(influential,2)
(unenhanced,1)
(GM-CSF,1)
(postmenopausal,4)
(lateral,1)
(0.70,1)
(refers,1)
(measurements,2)
(France,1)
(considerable,1)
(pathological,1)
(vehicles,1)
(delay,3)
(such,17)
(formed,1)
(missed,1)
(lincRNA-ROR,7)
(chemotherapy,20)
(seen,1)
(7/18,1)
(CONCLUSION,2)
(software,1)
(Tel,1)
(25,5)
(non-small,1)
(3-fold,1)
(correlate,1)
(engagement,1)
(required,5)
(substantially,3)
(19450,1)
(adjuvant,10)
(incorporation,1)
(anti-cancer,5)
(practice,2)
(feared,1)
(¹H,1)
(2016,2)
(Y537S,1)
(HS,4)
(2-5%,1)
(TCH-based,1)
(intended,1)
(elderly,1)
(tomosynthesis,1)
(GEM,3)
(Clinical,1)
(usually,1)
(phase,8)
(TAMs,4)
(mortality,25)
(tumor,41)
(Cases,1)
(malignancy,3)
(ensuring,1)
(Immortalized,1)
(bacteriophages,1)
(adenocarcinomas,1)
(had,20)
(across,1)
(ZEB-1,1)
(CXCL1,6)
(0.867,1)
(before,20)
(athymic,1)
(4.0%,1)
(1.3-20.9;,1)
(175,2)
(and/or,8)
(factor,16)
(dissection,1)
(progressive,1)
(95%CI0.004-0.403,1)
(similar,6)
(reviewed,2)
(team-based,1)
(patterns,4)
(Metastatic,2)
(India,1)
(physical,4)
(voxel-basis,1)
(onset,1)
(serve,4)
(files,1)
(pituitary,2)
(mode,5)
(Studies,2)
(modifications,2)
(processing,1)
(scarce,1)
(suffering,1)
(50,2)
(maintain,1)
(tools,5)
(mediated,2)
(﻿Antrodia,1)
(coronary,1)
(ejection,2)
(GSK525762A,1)
(product,1)
(successfully,1)
(potentially,3)
(Tamoxifen,1)
(Taken,2)
(exclusively,1)
(inhibitory,1)
(seroma,7)
(crucial,5)
(53.7,1)
(TNBC,25)
(goal,1)
(DTC,3)
(nMBCs,1)
(ranged,2)
(Grade,1)
(optoacoustic,1)
(epithelial,5)
(difficulty,1)
(PET,10)
(selected,2)
(immune,5)
(side,3)
(also,23)
(wider,1)
(somewhere,1)
(T3,1)
(significant,18)
(promotion,1)
(searched,2)
(questionnaire,2)
(RNA-seq,4)
(worm,1)
(scant,1)
(breast.Treatment,1)
(reported,11)
(Perugia,1)
(settings,2)
(evaluated,9)
(2%,1)
(dose-dependent,3)
(shaped,1)
([Mdiphos2]sac2,1)
(doseMTDand,1)
(strategy,9)
(down-regulating,1)
(Early,1)
(Wnt/β-catenin,1)
(It,9)
(AMED,1)
(membrane,5)
(Enrichment,1)
(2],1)
(regions,2)
(By,2)
(1.42,1)
(fractionation,2)
(presenting,2)
(beam,1)
(implication,1)
(inhibit,5)
(tandem,1)
(characteristic,1)
(complementation,1)
(expressed,7)
(external,1)
(chemokine,3)
(tumor's,1)
(post-grad,2)
(CEST,4)
(dense,1)
(consistently,2)
(addressed,1)
(support,8)
(cutaneous,1)
(spermatogenesis,1)
(course,3)
(hence,1)
(females,4)
(plant,2)
(highly,6)
(within,10)
(re-establish,1)
(ours,1)
(Hence,2)
(receive,1)
(key,2)
(steadily,1)
(Dissemination,1)
(cannot,1)
(various,6)
(another,1)
(90,1)
(succinocarboxamide,1)
(PCR,2)
(vasculature,2)
(15.9,1)
(to,297)
(know,1)
(core,1)
(antagonism,1)
(gemcitabineGEM,1)
(emphasizing,1)
(system-both,1)
(group,13)
(repeat,2)
(cancer-associated,1)
(where,2)
(kinase,4)
(normal,11)
(quantitative,3)
(statistics,1)
(HR=2.11,1)
(Raf,1)
(mapped,1)
(copyright,2)
(compliance,1)
(pulmonary,1)
(EXT-like,1)
(additional,4)
(familial,4)
(dynamic,5)
(value-based,2)
(it,17)
(three-photon,1)
(0.75-1.09,1)
(others,1)
(boost,3)
(focused,1)
(exposure,8)
(recommended,1)
(a-carotene,1)
(corresponding,2)
(spermatozoa,1)
(applications,6)
(centre,1)
(Diagnostic,1)
(To,6)
(Cardiac,1)
(these,17)
(Neutral,1)
(research,6)
(retinoic,1)
(release,1)
(Thirteen,1)
(techniques,4)
(beyond,2)
(indicated,3)
(apoptotic,4)
(carcinoma,10)
(determine,5)
(18,2)
(Italy,1)
(site,1)
(coating,1)
(transfected,1)
(inhibitors-based,1)
(contained,1)
(predictors,2)
(errors,2)
(Compound,1)
(RA,3)
(needle,1)
(p = 0.006,1)
(Aided,2)
(functional,4)
(collateral,1)
(constipation,1)
(ratio,5)
(signatures,6)
(follow-up,4)
(disturb,1)
(Based,3)
(concerns,2)
(treatments,6)
(suitable,2)
(undergone,2)
(precise,3)
(SEER,1)
(429,1)
(cooperative,1)
(2012,2)
(nu,1)
(nasal,1)
(fusions,1)
(limiting,1)
(sampling,4)
(relatives,4)
(laboratory,5)
(Most,2)
(demand,1)
(benefit,3)
(randomized,1)
(phenomenon,1)
(doubled,1)
(multi-omics,1)
(Bioluminescence,1)
(image,9)
(forms,2)
(suggested,3)
(reduction,5)
(cost-effective,1)
(or,54)
(Recent,1)
(improves,1)
(paucity,1)
(HER4,1)
(appointment,3)
(TAMs/CXCL1,1)
(inhibitor-,1)
(4.05,1)
(properties,7)
(EAC,1)
(of,653)
(induces,1)
(dependence,2)
(receptors,4)
(eligible,1)
(4/6,1)
(WB,1)
(therapies,14)
(functions,2)
(reference,1)
(microenvironment,1)
(endocrine-dependent,1)
(system,5)
(retinol,1)
(led,5)
(indices,2)
(disappointing,1)
(40.5,1)
(degraders,2)
(postpartum,7)
(LincRNA-ROR,1)
(fourier-transform,1)
(maintaining,1)
(ongoing,2)
(situ,1)
(clinical,37)
(describe,2)
(utilizing,3)
(demonstrates,1)
(simulation,1)
(metastatic,16)
(RCT,1)
(achieved,2)
(blot,2)
(cooperation,1)
(grade,7)
(jaundice,1)
(﻿Tumor-associated,1)
(remains,13)
(injection,2)
(tend,2)
(did,9)
(OBCS,4)
(38.7%,1)
(cardiac,4)
(toxicity,9)
(co-treatment,3)
(terms,3)
(1.8,2)
(manageable,1)
(atechnique,1)
(diseases,4)
(opsonization,1)
(Cochrane,2)
(clonal,2)
(maps,1)
(CSC,2)
(historically,1)
(1.4mg/m2,1)
(algorithm,3)
(locally-advanced,2)
(Observational,1)
(treatment;,1)
(NIRF,2)
(cancers,18)
(inquiry,1)
(exam,1)
(YBCS-relatives,1)
(feasible,2)
(relations,1)
(0.0001,1)
(associating,1)
(cessation,1)
(far,2)
(Though,1)
(MAN-MB-231,1)
(phosphorylates,1)
(MDA-MB-231,14)
(nipple-sparing,1)
(high-resolution,2)
(Surprisingly,1)
(recent,9)
(Of,1)
(quality,6)
(criteria,2)
(cardiotoxicities,1)
(0.009,1)
(multivariate,1)
(60%,1)
(whole,2)
(known,8)
(interdependence,1)
(meet,1)
(secreted,1)
(consumption,1)
(Antiestrogen,1)
(solid,1)
(18F-FDG,3)
(drugs,7)
(MM-231,8)
(taken,2)
(enzymes,1)
(autonomic,1)
(explaining,1)
(prolactinoma,4)
(24-80,1)
(dependent,2)
(3.2 months,1)
(malignant,3)
(OF,1)
(appealing,1)
(heavy,1)
(measuring,1)
(HPLC,1)
(that,117)
(context,3)
(hypofractionation,1)
(many,4)
(lobular,1)
(bisulfite,2)
(triggers,1)
(sensitivity,9)
(AION,6)
(strong,6)
(Finally,5)
(66-years-old,1)
(Certificate,1)
(protocols,4)
(EGFR-Pyk2-Src-Arg-cortactin,1)
(hyperinsulinaemia,1)
(insights,1)
(4-HBR,2)
(prognostication,1)
(regarding,2)
(Seroma,1)
(ranked,1)
(amplitude,1)
(BE,1)
(towavelet,1)
(United,2)
(worthwhile,1)
(homogeneous,1)
(whichever,1)
(co-encapsulation,1)
(0.45,1)
(next,1)
(neuroma,3)
(Extensive,1)
(repressed,2)
(bisphosphonate,3)
(neural,1)
(intervention,7)
(tamoxifen,10)
(loss,3)
(common,12)
(suspicion,1)
(classified,1)
(reports,1)
(VEGFA,1)
(35%,1)
(CI],2)
(schedule,1)
(registries,1)
(Future,1)
(OR,2)
(paradigm,2)
(inconsistent,3)
(chromatographic,1)
(face-to-face,1)
(spread,1)
(includes,1)
(penetration,2)
(not,39)
(illustrated,1)
(enable,3)
(conclusion,4)
(downregulated,7)
(recurrences,4)
(provided,4)
(longitudinally,1)
(Circular,1)
(modalities,3)
(At,3)
(68Ga-Pentixafor,5)
(82%,1)
(PsycInfo,1)
(everolimus-based,3)
(generated,2)
(perceived,3)
(become,1)
(subgroup,1)
(AND,1)
(postoperative,1)
(brothers,1)
(BIRC3,1)
(rights,2)
(exploit,1)
(PEGylated,1)
(tailor,1)
(increasing,5)
(1.78],1)
(cumulative,1)
(Additional,2)
(challenge,2)
(summarized,2)
('primary,1)
(N-cadherin,1)
(significance,2)
(on,68)
(database,5)
(suppressive,1)
(ICAM1,1)
(localized,1)
(ER-positive/human,1)
('biomarkers',1)
(prostatic,1)
(75%,1)
(MTR,3)
(exist,1)
(Management,1)
(random,2)
(300,1)
(Group,1)
(273 μm,1)
(3-O-p-coumaroyltormentic,2)
(outpatient,1)
(upregulating,3)
(deaths,7)
(overexpressed,2)
(-3.3,1)
(excessive,1)
(gadolinium-based,1)
(cases,27)
(pro-apoptotic,1)
(rs11555432,1)
(ET,3)
(alpelisib,3)
(Vietnamese,4)
(chemoresistance,1)
(RESON,1)
(use,27)
(Next,1)
(21,1)
(soon,2)
(follicles,1)
(college,1)
(Cosmetic,1)
(nanomolar,1)
(non-anthracycline-based,1)
(contains,1)
(compared,24)
(Evolution,1)
(triggered,1)
(remained,2)
(500000,1)
(possibility,4)
(simultaneous,1)
(glauca,1)
(headache,1)
(0.5,1)
(assessed,4)
(hepatitis,1)
(OV,1)
(characterize,1)
(lutein,1)
(decades,4)
(examined,7)
(metrics,2)
(34972,1)
(1444,1)
(These,12)
(viruses,4)
(activate,1)
(Importantly,1)
(phage,4)
(grape,1)
(definitive,1)
(extensive,3)
(updated,1)
(MCF7,1)
(confirms,1)
(hurdles,1)
(subcutaneous,5)
(suffer,1)
(injury,2)
(fatigue,1)
(colon,5)
(Green,1)
(should,1)
(detect,2)
(cell-only,1)
(Centre,1)
(prediction,3)
(latest,2)
(susceptibility,1)
(3-O-p-Coumaroyltormentic,1)
(up,7)
(T1-T3,2)
(diabetic,1)
(End,2)
(ontology,1)
(47,1)
(NST,1)
(Computer,2)
(reducing,2)
(progression,8)
(rates,6)
(limit,2)
(osteoporosis,2)
(Increasing,1)
(EXTL2,1)
(damage,7)
(BRCA1,17)
(August,1)
(gelation,1)
(cross-sectional,1)
(dyes,1)
(by,81)
(like,4)
(0of,1)
(guidelines,1)
(Similar,2)
(C,1)
(propidium,1)
([one,2)
(2PA,2)
(continuous,1)
(52723,1)
(epigenetic,4)
(painful,1)
(promise,2)
(facilitates,2)
(14,2)
(depends,1)
(cell-cycle,1)
(7,2)
(P=0.134,1)
(vector,1)
(growth,25)
(43.6,1)
(continue,2)
(Subgroup,3)
(mammalian,1)
(semi-quantitatively,1)
(persistent,2)
(satisfy,1)
(compound,5)
(integrated,3)
(inhibitor/mimic-,1)
(alignment,2)
(wide,1)
(sea,1)
(long-lived,1)
(based,9)
(extrinsic,1)
(variables,1)
(photographs,2)
(Many,1)
(refractory,1)
(intensity,1)
(Such,1)
(matrikines,1)
(every,1)
(approved,1)
(nature,2)
(deals,1)
(hydroxyl,2)
(extension,1)
(construct,1)
(557,1)
(underlines,1)
(clinicopathologic,1)
(Multivariate,1)
([1.14,1)
(transforms,1)
(deregulation,1)
(large,6)
(dedicated,2)
(local,1)
(20%,3)
(neutral,1)
(cosmetic,3)
(activity,17)
(biggest,1)
(hold,1)
(disruption,1)
(PARP,2)
(and,652)
(being,9)
(executed,1)
